Hydroquinone 6% | Hydrocortisone 0.5% | Tretinoin 0.05%

Route: Topical. Apply a thin layer to affected hyperpigmented lesions once nightly (or as directed). Allow skin to dry after cleansing (20–30 minutes) before applying to reduce tretinoin irritation. Apply to affected areas only; avoid periorbital skin, mucous membranes, and broken skin. Daily broad-spectrum sunscreen (SPF ≥30) is essential throughout treatment.

Dosing is prescriber-determined. Typical approach:

• Apply once nightly to affected areas for the prescribed duration.
• Gradual introduction (every other night) may be recommended initially given the combined irritant potential of HQ 6% and tretinoin 0.05%.
• Treatment cycles (typically 3 months on / 1 month off) may be recommended to limit corticosteroid and HQ adverse effects.
• Prescribers will individualize frequency and duration based on patient tolerability and response.

• Hydroquinone 6%: Competitively inhibits tyrosinase, disrupts melanosome synthesis and distribution, and at this concentration may exert selective melanocytotoxicity to reduce pigment production.
• Hydrocortisone 0.5%: Suppresses inflammatory mediators (prostaglandins, endothelin-1, GM-CSF) that activate melanocytes; reduces cytokine-driven melanogenesis and attenuates the skin irritation from the other two actives, improving tolerability and reducing post-inflammatory hyperpigmentation risk.
• Tretinoin 0.05%: Binds RAR-α/β/γ to normalize follicular epithelial differentiation, accelerates keratinocyte turnover (expelling melanin-laden corneocytes), inhibits tyrosinase expression, reduces melanin transfer, and enhances dermal penetration of hydroquinone for improved efficacy.

This triple combination is a refined version of the original Kligman formula (HQ 5% / tretinoin 0.1% / dexamethasone 0.1%) with a lower-potency corticosteroid and individualized concentrations, representing a well-established prescriber-directed approach for melasma and related hyperpigmentation. The combination targets three complementary mechanisms: melanin synthesis inhibition (HQ), keratinocyte turnover acceleration (tretinoin), and anti-inflammatory suppression of melanocyte activation (hydrocortisone).

Monitoring: Assess response and adverse effects at 4–8 weeks; watch for retinoid dermatitis, ochronosis (HQ 6% chronic use), anodermal atrophy (hydrocortisone), and photosensitivity. Enforce strict sunscreen use.

Contraindications:

• Known hypersensitivity to any component.
• Pregnancy: tretinoin is teratogenic; hydroquinone has systemic absorption — avoid in pregnancy unless benefit clearly outweighs risk.

Warnings & Precautions:

• Ochronosis risk with chronic HQ 6% use; cycle treatment with breaks.
• Retinoid dermatitis: erythema, peeling, photosensitivity — enforce rigorous photoprotection.
• Skin atrophy risk with chronic low-potency steroid use on facial skin; do not exceed prescribed duration.

Drug Interactions:

• Avoid concomitant irritating topicals (AHAs, benzoyl peroxide, other retinoids) without prescriber guidance.
• Photosensitizing systemic medications increase UV-damage risk with tretinoin.

Common Side Effects: Skin dryness, peeling, erythema, burning (particularly during initiation), photosensitivity, mild skin lightening of surrounding normal skin if applied imprecisely.

Store at room temperature (15°C–25°C). Protect from light and air — hydroquinone and tretinoin are both photosensitive; store in an opaque container. Keep tightly sealed. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding. Discard if product discolors (browns) indicating oxidation.

Why are three ingredients combined in this formula?

Each ingredient targets a different mechanism of hyperpigmentation: HQ 6% blocks melanin synthesis, tretinoin 0.05% accelerates melanin-laden skin cell shedding and enhances HQ penetration, and hydrocortisone 0.5% reduces inflammation that drives melanocyte activation. Together they produce superior results compared to any single agent.

Why is hydrocortisone included?

Low-dose hydrocortisone reduces the inflammatory and melanocyte-stimulating signals (prostaglandins, endothelin-1) that worsen hyperpigmentation, and also reduces the irritation from HQ and tretinoin — improving tolerability and reducing the risk of post-inflammatory hyperpigmentation from therapy itself.

How long should I use this medication?

Your prescriber will define the treatment cycle. Typically, 3-month treatment cycles with breaks are used to minimize the risk of ochronosis (from HQ) and skin thinning (from hydrocortisone). Do not use longer than directed without reassessment.

Is this FDA-approved?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug. A commercially available Tri-Luma® formulation with similar components exists, but compounded preparations allow individualized concentrations.

Can I use this during the day?

This preparation should be used nightly, as tretinoin increases photosensitivity. Daily broad-spectrum sunscreen (SPF ≥30) is mandatory during treatment; sun exposure during the day will counteract the depigmenting effects.